Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ekso Bionics Holdings (EKSO) Gross Margin (2016 - 2026)

Ekso Bionics Holdings has reported Gross Margin over the past 13 years, most recently at 53.22% for Q4 2025.

  • On a quarterly basis, Gross Margin fell 10.0% to 53.22% in Q4 2025 year-over-year; TTM through Dec 2025 was 53.48%, a 42.0% increase, with the full-year FY2025 number at 53.48%, up 42.0% from a year prior.
  • Gross Margin reached 53.22% in Q4 2025 per EKSO's latest filing, down from 60.3% in the prior quarter.
  • The five-year high for Gross Margin was 64.66% in Q1 2021, with the low at 39.82% in Q2 2025.
  • The 5-year median for Gross Margin is 53.24% (2024), against an average of 52.67%.
  • Peak YoY movement for Gross Margin: skyrocketed 2127bps in 2021, then tumbled -1756bps in 2022.
  • Tracing EKSO's Gross Margin over 5 years: stood at 59.25% in 2021, then decreased by -20bps to 47.25% in 2022, then increased by 3bps to 48.88% in 2023, then grew by 9bps to 53.32% in 2024, then fell by 0bps to 53.22% in 2025.
  • According to Business Quant data, Gross Margin over the past three periods came in at 53.22%, 60.3%, and 39.82% for Q4 2025, Q3 2025, and Q2 2025 respectively.